Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 1
2012 8
2013 4
2014 3
2015 4
2016 4
2018 2
2019 2
2020 3
2021 1
2022 1
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death.
Mannion J, Gifford V, Bellenie B, Fernando W, Ramos Garcia L, Wilson R, John SW, Udainiya S, Patin EC, Tiu C, Smith A, Goicoechea M, Craxton A, Moraes de Vasconcelos N, Guppy N, Cheung KJ, Cundy NJ, Pierrat O, Brennan A, Roumeliotis TI, Benstead-Hume G, Alexander J, Muirhead G, Layzell S, Lyu W, Roulstone V, Allen M, Baldock H, Legrand A, Gabel F, Serrano-Aparicio N, Starling C, Guo H, Upton J, Gyrd-Hansen M, MacFarlane M, Seddon B, Raynaud F, Roxanis I, Harrington K, Haider S, Choudhary JS, Hoelder S, Tenev T, Meier P. Mannion J, et al. Among authors: roulstone v. Immunity. 2024 Jul 9;57(7):1514-1532.e15. doi: 10.1016/j.immuni.2024.04.025. Epub 2024 May 23. Immunity. 2024. PMID: 38788712 Free article.
Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
Chiu M, Armstrong EJL, Jennings V, Foo S, Crespo-Rodriguez E, Bozhanova G, Patin EC, McLaughlin M, Mansfield D, Baker G, Grove L, Pedersen M, Kyula J, Roulstone V, Wilkins A, McDonald F, Harrington K, Melcher A. Chiu M, et al. Among authors: roulstone v. Expert Opin Biol Ther. 2020 Jun;20(6):635-652. doi: 10.1080/14712598.2020.1729351. Epub 2020 Feb 23. Expert Opin Biol Ther. 2020. PMID: 32067509 Review.
Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy.
Patin EC, Nenclares P, Chan Wah Hak C, Dillon MT, Patrikeev A, McLaughlin M, Grove L, Foo S, Soliman H, Barata JP, Marsden J, Baldock H, Gkantalis J, Roulstone V, Kyula J, Burley A, Hubbard L, Pedersen M, Smith SA, Clancy-Thompson E, Melcher AA, Ono M, Rullan A, Harrington KJ. Patin EC, et al. Among authors: roulstone v. Nat Commun. 2024 Aug 13;15(1):6923. doi: 10.1038/s41467-024-51236-6. Nat Commun. 2024. PMID: 39134540 Free PMC article.
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling.
Armstrong E, Chiu MKL, Foo S, Appleton L, Nenclares P, Patrikeev A, Mohan N, Mclaughlin M, Bozhanova G, Hoebart J, Roulstone V, Patin E, Pedersen M, Kyula J, Ono M, Errington-Mais F, Bell J, Harrington KJ, Melcher A, Jennings V. Armstrong E, et al. Among authors: roulstone v. J Immunother Cancer. 2024 Jul 25;12(7):e009443. doi: 10.1136/jitc-2024-009443. J Immunother Cancer. 2024. PMID: 39060020 Free PMC article.
Synergistic antitumour effects of rapamycin and oncolytic reovirus.
Comins C, Simpson GR, Rogers W, Relph K, Harrington K, Melcher A, Roulstone V, Kyula J, Pandha H. Comins C, et al. Among authors: roulstone v. Cancer Gene Ther. 2018 Jun;25(5-6):148-160. doi: 10.1038/s41417-018-0011-8. Epub 2018 May 3. Cancer Gene Ther. 2018. PMID: 29720674
RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma.
Smith HG, Jamal K, Dayal JH, Tenev T, Kyula-Currie J, Guppy N, Gazinska P, Roulstone V, Liccardi G, Davies E, Roxanis I, Melcher AA, Hayes AJ, Inman GJ, Harrington KJ, Meier P. Smith HG, et al. Among authors: roulstone v. EMBO Mol Med. 2020 Jun 8;12(6):e10979. doi: 10.15252/emmm.201910979. Epub 2020 May 18. EMBO Mol Med. 2020. PMID: 32419365 Free PMC article.
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
Bozhanova G, Hassan J, Appleton L, Jennings V, Foo S, McLaughlin M, Chan Wah Hak CM, Patin EC, Crespo-Rodriguez E, Baker G, Armstrong E, Chiu M, Pandha H, Samson A, Roulstone V, Kyula J, Vile R, Errington-Mais F, Pedersen M, Harrington K, Ono M, Melcher A. Bozhanova G, et al. Among authors: roulstone v. J Immunother Cancer. 2022 Mar;10(3):e004410. doi: 10.1136/jitc-2021-004410. J Immunother Cancer. 2022. PMID: 35338089 Free PMC article.
34 results